Myelodysplastic syndromes trials in Italy

In Italy 28 Also abroad 369

28 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Not yet taking people in Italy
Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
Where
Bologna, Ravenna
Age
18 years and over
People
126 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT07929740 · EU 2025-524332-19-00
Phase 3Taking people
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Where
Ancona, Candiolo, Florence, Milan, Pavia, Reggio Calabria, Rome, Rozzano, Turin
Age
18 years and over
People
225 worldwide
Run by
Takeda
See details and how to joinNCT06499285 · EU 2024-516009-22-00
Phase 3Taking people
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
Where
Bologna, Candiolo, Florence, Milan, Naples, Novara, Padova, Pavia, Rome, Rozzano
Age
18 years and over
People
300 worldwide
Run by
Takeda
See details and how to joinNCT07422480 · EU 2025-523544-12-00
Phase 1Taking people
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Where
Bergamo, Pisa, Rozzano
Age
18 years and over
People
78 worldwide
Run by
Genmab
See details and how to joinNCT07384715 · EU 2025-523101-15-00
Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Bologna, Ravenna
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
Phase 2Taking people
Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
Where
Alessandria, Bologna, Candiolo, Milan
Age
18 years and over
People
90 worldwide
Run by
Faron Pharmaceuticals Ltd
See details and how to joinNCT07672769 · EU 2026-526706-33-00
Phase 2Taking people
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
Where
Milan, Padova, Reggio Emilia, Roma
Age
18 years and over
People
156 worldwide
Run by
Swedish Orphan Biovitrum
See details and how to joinNCT06782373 · EU 2024-516347-41-00
Phase 3Taking people
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Where
Candiolo, Ferrara, Florence, Meldola, Milan, Novara, Ravenna, Rome, Rozzano, Torino, Varese
Age
18 years and over
People
490 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06641414 · EU 2024-517247-31-00
Phase 2/3Taking people
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Where
Bologna, Florence, Milan, Novara, Ravenna, Rome, Turin
Age
18 years and over
People
316 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00
Phase 4Taking people
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
Where
Bologna, Busto Arsizio, Milan, Modena, Novara, Padova, Perugia, Pescara, Ravenna, Rimini, Rome
Age
18 years and over
People
365 worldwide
Run by
Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00
Phase 1/2Taking people
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Where
Candiolo, Firenze
Age
18 years and over
People
150 worldwide
Run by
Groupe Francophone des Myelodysplasies
See details and how to joinNCT05181735 · EU 2024-515354-24-00
Phase 2Enrolling by invitation
RVU120 Rollover Study
Where
Bari
Age
18 years and over
People
14 worldwide
Run by
Ryvu Therapeutics SA
See details and how to joinNCT06987058 · EU 2025-521673-14-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Bologna, Florence, Salerno, Verona
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Bologna, Meldola, Milan
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
No phaseTaking people
Italian Network MDS Registry
Where
Alessandria, Ancona, Asti, Bari, Bologna, Cagliari, Candiolo, Chieri, Florence, Genova, Orbassano, Padova, Parma, Perugia, Pesaro, Rionero in Vulture, Torino, Tricase
Age
18 years to 106 years
People
10,000
Run by
Fondazione Italiana Sindromi Mielodisplastiche-ETS
See details and how to joinNCT02808858
Phase 3Taking people
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Where
Ancona, Bologna, Florence, Pavia, Rome, Rozzano, Turin
Age
18 years and over
People
48 worldwide
Run by
Institut de Recherches Internationales Servier
See details and how to joinNCT06465953 · EU 2023-510155-37-00
Phase 2Enrolling by invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Where
Milan
Age
18 years and over
People
332 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01
Phase 1/2Not yet taking people in Italy
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
Where
Bologna, Naples, Padova, Pavia, Rozzano
Age
18 years and over
People
64 worldwide
Run by
Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00
Phase 3Taking people
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Where
Allessandria, Bologna, Brindisi, Cagliari, Ferrara, Florence, Genoa, Lecce, Milan, Modena, Naples, Orbassano, Pavia, Reggio Calabria, Roma, Rozzano, Varese, Verona
Age
18 years and over
People
665 worldwide
Run by
Celgene
See details and how to joinNCT04064060
Phase 2Taking people
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Where
Catania, Florence, Milan, Orbassano, Rozzano, Udine
Age
18 years and over
People
80 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06847867 · EU 2024-519928-24-00
Phase 1/2Taking people
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Where
Bologna, Busto Arsizio, Genoa, Meldola, Padua, Perugia, Ravenna, Rome, Turin
Age
12 years and over
People
606 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555
Phase 2Taking people
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
Where
Bologna, Cagliari, Florence, Genoa, Milan, Modena, Naples, Pavia
Age
18 years to 64 years
People
90 worldwide
Run by
Pharmacosmos A/S
See details and how to joinNCT05693909 · EU 2023-507396-21-00
Phase 2Taking people
Eltrombopag for the treatment of thrombocytopenia due to low - and intermediate risk myelodysplastic syndromes.
Where
Bari, Firenze, Genova, Milano, Reggio Calabria, Roma, Rome, A.O.U Maggiore della Carità
Age
18 years and over
People
160
Run by
Associazione Qol-One
See details and how to joinNCT02912208 · EU 2024-520133-72-00
Phase 3Taking people
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
Where
Alexandria, Ancona, Ascoli Piceno, Bari, Bologna, Brescia, Brindisi, Castelfranco Veneto, Catania, Cuneo, Ferrara, Foggia, Latina, Lecce, Mestre - Venezia, Milan, Modena, Monza, Naples, Palermo, Pescara, Piacenza, Pisa, Reggio Calabria, Reggio Emilia, Rimini, Roma, Rome, Salerno, Sassari, Siena, Tricase, Turin, Udine, Verona, Viterbo
Age
18 years to 70 years
People
274
Run by
Gruppo Italiano Malattie EMatologiche dell'Adulto
See details and how to joinNCT04184505 · EU 2023-510515-19-00
Phase 2Taking people
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Where
Genoa, Rozzano
Age
18 years to 99 years
People
42
Run by
Istituto Clinico Humanitas
See details and how to joinNCT06892223 · EU 2024-516974-31-00